{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:28:21Z","timestamp":1760218101649,"version":"3.37.3"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,14]]},"DOI":"10.1093\/ehjcvp\/pvae052","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T13:44:28Z","timestamp":1723643068000},"page":"367-369","source":"Crossref","is-referenced-by-count":2,"title":["The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6942-6312","authenticated-orcid":false,"given":"Stefan","family":"Agewall","sequence":"first","affiliation":[{"name":"Editor-in-Chief"},{"name":"Institute of Clinical Sciences, Karolinska Institute of Danderyd , Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"2024081413441874600_bib1","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2024081413441874600_bib2","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"2024081413441874600_bib3","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1093\/eurheartj\/ehab702","article-title":"Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR","volume":"42","author":"Escaned","year":"2021","journal-title":"Eur Heart J"},{"key":"2024081413441874600_bib4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/ehjcvp\/pvad008","article-title":"Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial","volume":"9","author":"Lee","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib5","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/ehjcvp\/pvad027","article-title":"Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes-a substudy of the TROPICAL-ACS trial","volume":"9","author":"Kom\u00f3csi","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ehjcvp\/pvac020","article-title":"Extended, standard, or de-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis","volume":"8","author":"Ullah","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/ehjcvp\/pvab068","article-title":"Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis","volume":"8","author":"Tavenier","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"key":"2024081413441874600_bib9","first-page":"10","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet North Am Ed"},{"key":"2024081413441874600_bib10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) investigators","volume":"346","author":"Stone","year":"2002","journal-title":"N Engl J Med"},{"key":"2024081413441874600_bib11","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors\u2014pharmacology and clinical applications 20 years after sildenafil discovery","volume":"175","author":"Andersson","year":"2018","journal-title":"Br J Pharmacol"},{"key":"2024081413441874600_bib12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCULATIONAHA.111.023838","article-title":"Epidemiology and genetics of sudden cardiac death","volume":"125","author":"Deo","year":"2012","journal-title":"Circulation"},{"key":"2024081413441874600_bib13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"key":"2024081413441874600_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/ehjcvp\/pvac041","article-title":"Non-steroidal anti-inflammatory drugs and risk of myocardial infarction adjusting for use of proton pump-inhibitors in patients with no major risk factors: a nested case-control study in the UK Clinical Practice Research Datalink","volume":"9","author":"Baak","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib15","doi-asserted-by":"crossref","first-page":"l1580","DOI":"10.1136\/bmj.l1580","article-title":"Estimates of all-cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study","volume":"365","author":"Xie","year":"2019","journal-title":"BMJ"},{"key":"2024081413441874600_bib16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/ehjcvp\/pvab070","article-title":"Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Ortega-Paz","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/ehjcvp\/pvad058","article-title":"Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study","volume":"9","author":"Chan","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/ehjcvp\/pvab089","volume":"8","author":"Bonaca","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib19","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1055\/a-1742-0177","article-title":"Incidence and outcomes associated with 6,841 isolated distal deep vein thromboses in patients with 13 common cancers","volume":"122","author":"Mahajan","year":"2022","journal-title":"Thromb Haemost"},{"key":"2024081413441874600_bib20","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1161\/CIRCULATIONAHA.123.066360","article-title":"Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis (ONCO DVT study): an open-label, multicenter, randomized clinical trial","volume":"148","author":"Yamashita","year":"2023","journal-title":"Circulation"},{"key":"2024081413441874600_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/ehjcvp\/pvac001","article-title":"SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis","volume":"8","author":"Razuk","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/ehjcvp\/pvab056","article-title":"Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence","volume":"8","author":"Aguilar-Gallardo","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ehjcvp\/pvad033","article-title":"Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study","volume":"9","author":"J\u00fal\u00edusd\u00f3ttir","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib24","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1093\/ehjcvp\/pvac004","article-title":"Are SGLT2 inhibitors effective against \u2018all\u2019 heart failure with preserved ejection fraction?","volume":"8","author":"Hasegawa","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/ehjcvp\/pvad053","article-title":"The effect of SGLT2 inhibitors on the endothelium and the microcirculation: from bench to bedside and beyond","volume":"9","author":"Dimitriadis","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/ehjcvp\/pvad070","article-title":"Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study","volume":"9","author":"Grymonprez","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib27","first-page":"336","article-title":"Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients","volume-title":"Eur Heart J Cardiovasc Pharmacother","year":"2022"},{"key":"2024081413441874600_bib28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ehjcvp\/pvab032","article-title":"Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients","volume":"8","author":"Chen","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib29","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1093\/ehjcvp\/pvab081","article-title":"Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021","volume":"8","author":"Mone","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Capodanno","year":"2022","journal-title":"Eur Heart J"},{"key":"2024081413441874600_bib31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/ehjcvp\/pvad003","article-title":"Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-analysis of randomized controlled trials","volume":"9","author":"Guedeney","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413441874600_bib32","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1096\/fj.04-2748com","article-title":"Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI","volume":"19","author":"Penz","year":"2005","journal-title":"FASEB J"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/5\/367\/58818478\/pvae052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/5\/367\/58818478\/pvae052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T13:44:55Z","timestamp":1723643095000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/5\/367\/7733500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,8,14]]},"published-print":{"date-parts":[[2024,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae052","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"type":"print","value":"2055-6837"},{"type":"electronic","value":"2055-6845"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,8]]}}}